Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROSSING phase 3 trial of tezepelumab in eosinophilic esophagitis
CTR20231101Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tezepelumab in eosinophilic esophagitis (EoE), sponsored by AstraZeneca. Started Jun 2024; status: active.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on CTR20231101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231101.